Cga - glycoprotein hormones, alpha polypeptide Gene
Also Known as Gpa1
Species: Rattus norvegicus
Gene Type: protein coding
Gene ID: 116700
Summary
Predicted to enable follicle-stimulating hormone activity. Predicted to be involved in several processes, including positive regulation of steroid biosynthetic process; regulation of signaling receptor activity; and thyroid hormone generation. Predicted to act upstream of or within several processes, including gonadotropin secretion; negative regulation of organ growth; and thyroid gland development. Predicted to be part of follicle-stimulating hormone complex. Predicted to be active in extracellular space. Orthologous to human CGA (glycoprotein Hormones, alpha polypeptide). [provided by Alliance of Genome Resources, Apr 2022]
Cga Products (1)
| mRNA | Protein | Name |
|---|---|---|
| NM_053918.3 | NP_446370.3 | glycoprotein hormones alpha chain precursor |
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
glycoprotein hormones alpha chain |
|
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(1)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-B0621 | Triclabendazole | Inhibitor | 99.36% | Yes |
Clinical Phase
Bioactive Molecules
(4)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-148511 | Vidutolimod | 93.85% | Phase 3 | |
| HY-13902 | Berzosertib | 99.67% | Phase 2 | |
| HY-150724 | ODN 1018 | Agonist | 99.28% | Phase 2 |
| HY-13735H | Quinacrine acetate | / | Phase 2 |
Pre-clinical Phase
Bioactive Molecules
(110)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-114180 | RU.521 | Inhibitor | 99.95% | Unkown |
| HY-131454 | SR-717 | Agonist | 99.89% | Unkown |
| HY-133916 | G140 | Inhibitor | 99.17% | Unkown |
| HY-128583 | G150 | Inhibitor | 99.20% | Unkown |
| HY-160225 | ISD sodium | 98.02% | Unkown | |
| HY-150741 | ODN 2216 | 98.57% | Unkown | |
| HY-150751 | ODN TTAGGG | 99.87% | Unkown | |
| HY-114182 | PF-06928215 | Inhibitor | 99.68% | Unkown |
| HY-P1680 | Astin C | Inhibitor | 99.47% | Unkown |
| HY-150751C | ODN TTAGGG sodium | Antagonist | 93.80% | Unkown |
| HY-W021040 | Fludioxonil | 99.94% | Unkown | |
| HY-172208 | PROTAC cGAS degrader-1 | Degrader | 99.07% | Unkown |
| HY-139056 | SU0268 | Inhibitor | 99.96% | Unkown |
| HY-160546 | cGAS-IN-2 | Inhibitor | 99.67% | Unkown |
| HY-150750 | ODN M362 | 96.01% | Unkown | |
| HY-P5997 | XQ2B | Inhibitor | 99.45% | Unkown |
| HY-149526 | cGAS-IN-1 | Inhibitor | 98.21% | Unkown |
| HY-123230 | Trifloxystrobin | Inhibitor | 99.49% | Unkown |
| HY-164288 | TDI-6570 | Inhibitor | 99.64% | Unkown |
| HY-114181 | IRAK4-IN-4 | Inhibitor | 99.55% | Unkown |
| HY-170362 | cGAS-IN-4 | Inhibitor | 99.28% | Unkown |
| HY-131454A | SR-717 free acid | Agonist | 99.36% | Unkown |
| HY-124700 | LYPLAL1-IN-1 | 99.9% | Unkown | |
| HY-174801 | XL-3156 | Inhibitor | 99.91% | Unkown |
| HY-B0821 | Pymetrozine | Inhibitor | ≥99.0% | Unkown |
| HY-116214 | Cyprodinil | 98.84% | Unkown | |
| HY-141831 | STF-1084 | Inhibitor | 99.92% | Unkown |
| HY-158045 | PROTAC PARP1 degrader-1 | Degrader | 99.86% | Unkown |
| HY-174802 | XL-3158 | Inhibitor | 99.55% | Unkown |
| HY-N2616 | Vomicine | Inhibitor | 99.85% | Unkown |
| HY-B1331 | Cyromazine | 99.79% | Unkown | |
| HY-170362A | (R)-cGAS-IN-4 | Control | 99.94% | Unkown |
| HY-171692 | G3-YSD | 98.37% | Unkown | |
| HY-RS02576 | CGAS Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-177338 | STING agonist-45 | Agonist | 99.10% | Unkown |
| HY-132221 | CU-32 | Inhibitor | 98.8% | Unkown |
| HY-123230R | Trifloxystrobin (Standard) | Inhibitor | 99.15% | Unkown |
| HY-116214R | Cyprodinil (Standard) | 99.04% | Unkown | |
| HY-150742 | ODN 2336 | Agonist | 90.74% | Unkown |
| HY-150747 | ODN 6016 | Inducer | 94.95% | Unkown |
| HY-150748 | ODN D-SL01 | Agonist | 99.94% | Unkown |
| HY-160225F | Biotin-labeled ISD sodium | / | Unkown | |
| HY-RS02577 | Cgas Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W411604 | tert-Butyl hex-5-ynoate | / | Unkown | |
| HY-118578 | Furalaxyl | Inhibitor | 99.3% | Unkown |
| HY-12464 | Butafenacil | 98.99% | Unkown | |
| HY-184095 | Iptocigistat | Inhibitor | / | Unkown |
| HY-115763 | 3-Aminopropylphosphinic acid | Agonist | / | Unkown |
| HY-116214S | Cyprodinil-d5 | / | Unkown | |
| HY-116214S1 | Cyprodinil-13C6 | / | Unkown | |
| HY-123230S | Trifloxystrobin-d6 | Inhibitor | / | Unkown |
| HY-123230S1 | Trifloxystrobin-d3 | / | Unkown | |
| HY-13902A | Berzosertib hydrochloride | 98.77% | Unkown | |
| HY-139678 | SC13 | / | Unkown | |
| HY-144328 | STING agonist-10 | Activator | / | Unkown |
| HY-144329 | STING agonist-11 | Activator | / | Unkown |
| HY-147129 | cGAS-IN-9 | Inhibitor | / | Unkown |
| HY-148412 | Monarsen | Inhibitor | / | Unkown |
| HY-150213 | ODN BW001 | Inhibitor | / | Unkown |
| HY-150751A | Biotin-labeled ODN TTAGGG sodium | / | Unkown | |
| HY-150751B | FITC-labeled ODN TTAGGG sodium | Antagonist | / | Unkown |
| HY-158126 | G-quadruplex ligand 2 | Inhibitor | / | Unkown |
| HY-159925 | QKY-613 | Activator | 98.24% | Unkown |
| HY-162459 | cGAS-IN-3 | Inhibitor | / | Unkown |
| HY-162944 | NA-Ir | / | Unkown | |
| HY-162966 | MS7829 | Activator | / | Unkown |
| HY-162967 | MS8588 | Degrader | / | Unkown |
| HY-163461 | 4F-DDC | Inhibitor | / | Unkown |
| HY-169225 | PDIC-NN | Inducer | / | Unkown |
| HY-169225A | PDIC-NN dimethanesulfonate | / | Unkown | |
| HY-172218 | Lenalidomide-hex-5-ynoic acid | / | Unkown | |
| HY-175472 | (GalNAc)3-CPT | / | Unkown | |
| HY-176256 | endo-S-cGAFMP | Agonist | / | Unkown |
| HY-178032 | PARP1-IN-44 | / | Unkown | |
| HY-178431 | MT-44 | / | Unkown | |
| HY-179147 | cGAS-IN-6 | Inhibitor | / | Unkown |
| HY-179624 | cGAS-IN-7 | Inhibitor | / | Unkown |
| HY-180211 | cGAS-IN-8 | Inhibitor | / | Unkown |
| HY-180555 | SN38-(PEG)2-Pom-α | Activator | / | Unkown |
| HY-181850 | Telomeric G4s ligand 2 | / | Unkown | |
| HY-182360 | Cytisine-platinum(IV) prodrug-1 | / | Unkown | |
| HY-182758 | Topoisomerase I-IN-21 | / | Unkown | |
| HY-182926 | Topoisomerase I/II-IN-9 | Inhibitor | / | Unkown |
| HY-183748 | XL-20 | / | Unkown | |
| HY-B0621S | Triclabendazole-d3 | / | Unkown | |
| HY-B0621S1 | Triclabendazole-13C,d3 | Inhibitor | / | Unkown |
| HY-B1331S1 | Cyromazine-13C3 | / | Unkown | |
| HY-N12507 | Eupenicisirenin C | Inhibitor | / | Unkown |
| HY-N15159 | Cladophorol A | Inhibitor | / | Unkown |
| HY-P3041 | Chromostatin (bovine) | Inhibitor | / | Unkown |
| HY-P3864 | Pancreastatin (37-52), human | Inhibitor | / | Unkown |
| HY-RS02575 | CGA Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS02578 | Cgas Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS02624 | CHGA Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W020788 | Benoxacor | 99.39% | Unkown | |
| HY-114730 | CGA-JK3 | Inhibitor | / | Unkown |
| HY-121165 | Cymiazole | / | Unkown | |
| HY-165620 | Etacelasil | / | Unkown | |
| HY-RS17789 | Cga Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS18918 | Chga Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS24257 | Cga Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W010319S | 2-Amino-4-methoxy-6-methyl-1,3,5-triazine-d3 | / | Unkown | |
| HY-W021040S | Fludioxonil-13C3 | / | Unkown | |
| HY-W289054S | (S)-Metolachlor metabolite CGA 50720-d3 | / | Unkown | |
| HY-W681867 | Fluxofenim | 98.03% | Unkown | |
| HY-W707416S | N-(2,6-Dimethylphenyl)-N-(2-(methoxy-d3)acetyl)alanine | / | Unkown | |
| HY-W714168S | (rac)-Metolachlor metabolite CGA 351916-d3 | / | Unkown | |
| HY-W714705S | (S)-Metolachlor metabolite CGA 368208-d3 sodium salt | / | Unkown | |
| HY-W722289S | (rac)-Metolachlor metabolite CGA 50267-d3 | / | Unkown | |
| HY-W751253 | Dofenapyn | / | Unkown |
Bioactive MoleculesInhibitory Antibodies
(1)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P990181 | Anti-Mouse myeloperoxidase/MPO Antibody (6G4) | Inhibitor | 95.00% | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service